Warrington’s Windtree Therapeutics Succeeds in Trial of COVID-Related Lung Distress Treatment

By

finger pointing at picture
Image via Anna Shvets at Pexels.
Windtree Therapeutics, Warrington, is testing treatment of lungs compromised by COVID-19 or other respiratory conditions.

A Phase 2 test by Windtree Therapeutics of its drug treatment for Associated Acute Respiratory Distress Syndrome (ARDS) may hold hope for patients with damaged lungs.

The trial results from the Warrington biopharma company could represent progress in healing lungs affected by COVID-19 and other conditions that cause a build-up of fluid that compromises breathing.

Because ARDS affects so many other crucial body functions by reducing blood oxygen levels, it can be fatal.

Windtree sought to increase lungs efficacy of the lungs with a lucinactant, a liquid medication that encourages the lining of the lung to properly exchange oxygen with carbon dioxide.

The trial enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19–associated ARDS. Patients received lucinactant and were assessed for safety and tolerability.

Oxygenation and other physiological responses were also measured.

The trial showed the lucinactant as:

  • Generally safe, well tolerated, and faster to administer
  • Maintaining or improving oxygenation for the critically ill patients receiving it
  • Appropriate for further development as a treatment for ARDS and COVID-19 patients

“We are pleased to report these study results which demonstrate the feasibility of lucinactant delivered as a liquid via the endotracheal tube in treating critically ill patients who are intubated and mechanically ventilated due to severe COVID-19 associated ARDS,” said Steve Simonson, MD, Chief Medical Officer of Windtree Therapeutics.

Connect With Your Community

Subscribe for stories that matter!

"*" indicates required fields

Hidden
BT Yes
This field is for validation purposes and should be left unchanged.
Advertisement